Key result
Thrombomodulin immunostaining was positive in 96 of 106 primary transitional cell carcinomas, distinguishing them from renal cell carcinomas and adenocarcinomas, but not squamous cell carcinomas.
Why the study?
Does immunostaining for Thrombomodulin (TM) have practical value in the diagnosis of transitional cell carcinomas (TCCs)?
Observational (n=368)
Does immunostaining for Thrombomodulin (TM) have practical value in the diagnosis of transitional cell carcinomas (TCCs)?
Thrombomodulin immunostaining is a sensitive marker for transitional cell carcinoma and can help distinguish it from renal cell carcinomas and certain adenocarcinomas, but not from squamous cell carcinomas.
No takes yet. Share an insight, caveat, or question.
Thrombomodulin immunostaining may aid TCC differentiation from RCC and adenocarcinomas; cross-sectional data leave its routine diagnostic role open pending validation.
Nelson G. Ordóǹez (1998) conducted an observational in Transitional Cell Carcinoma (n=368). Thrombomodulin immunostaining vs. Other tumor types (renal cell carcinomas, adenocarcinomas, squamous cell carcinomas) was evaluated on Thrombomodulin expression. Thrombomodulin immunostaining was positive in 96 of 106 primary transitional cell carcinomas, distinguishing them from renal cell carcinomas and adenocarcinomas, but not squamous cell carcinomas.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: